Although angiotensin-converting enzyme inhibitors and Ang II receptor blockers are expected to prevent type 2 diabetes and obesity-associated metabolic disorders47,48,56, this study implies that they might affect some aspects of systemic glucose metabolism through brown adipocytes and other metabolic cells. This evidence concerns the gene ACE and obesity disorder.